Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on innovative solutions for serious viral infectious diseases, has announced the granting of stock options to four newly hired non-executive employees as a material inducement to join the company. On March 1, 2026, Invivyd authorized options to purchase a total of 192,000 shares of its common stock at an exercise price of $1.69, which corresponds to the closing stock price on February 27, 2026, the last trading day before the grant.

The stock options were issued in compliance with Nasdaq Listing Rule 5635(c)(4) and under the terms of the Invivyd, Inc. 2026 Inducement Plan. Each granted option is structured to vest over a four-year period, with 25% vesting on the first anniversary of the employee's start date, and the remainder vesting in equal monthly installments thereafter, contingent upon the employee's ongoing service with Invivyd. The options carry a term of 10 years, reflecting the company's commitment to attracting and retaining top talent in the biopharmaceutical industry.

Invivyd has positioned itself uniquely in the biotech sector through its proprietary technology platform, which aims to develop and adapt antibody solutions for viral infections, starting with SARS-CoV-2. In March 2024, the company secured emergency use authorization from the U.S. FDA for one of its monoclonal antibody candidates, underscoring its innovative approach to combating viral diseases. For further information about Invivyd and its advancements, interested parties can visit their website at https://invivyd.com/.

For media and investor inquiries, the company has provided dedicated contact channels for timely communication.

Invivyd, Inc. (Nasdaq: IVVD) recently announced the granting of stock options to new non-executive employees, aligning their interests with shareholder growth and company performance. This move, executed under Nasdaq Listing Rule 5635(c)(4), reflects a strategic approach to talent acquisition and employee retention within the competitive biopharmaceutical sector. The options, totaling 192,000 shares at an exercise price of $1.69—equivalent to the stock's closing price just before the grant—encourages employees to invest in the company's success.

From a market perspective, this incentive structure can serve multiple strategic purposes. Firstly, offering equity in the form of stock options can significantly enhance motivation and productivity among employees, fostering a culture of ownership that aligns their goals with that of the company. This is particularly critical in biopharma, where innovation is key, and rapid adaptation to changing market conditions can determine success.

Additionally, the vesting schedule (25% at the first anniversary and the rest monthly over the next three years) ensures that employees are incentivized to stay long-term, which can help mitigate turnover costs and retain crucial talent in a field where expertise is indispensable. Given that Invivyd is focused on developing innovative therapies, such as monoclonal antibodies for viral diseases, retaining skilled workers will be paramount as it navigates ongoing product development and potential regulatory hurdles.

Investors should view this move positively as it underscores Invivyd's commitment to fostering a dedicated workforce poised to drive R&D advancements and growth. However, potential investors should also exercise caution, keeping an eye on the company's progress and market dynamics, especially as it competes within a rapidly evolving landscape. A robust employee incentive plan is promising, but sustained performance will require strategic execution beyond just hiring talent.